A clinical trial pitting MRI against a burgeoning PET/CT technique has found the de facto defending champion better at revealing the presence of any grade of prostate cancer.

Two emerging MRI techniques show promise as all-in-one imaging tests for patients with pain in and below the lower back due to changes in the sacroiliac joint.

The FDA is warning patients and referrers about an imaging business near the nation’s capital that has fumbled away its mammography accreditation.

The FDA has cleared a focused-ultrasound developer to compare the safety and efficacy of acoustic energy for treating prostate cancer against the more conservative approach of active surveillance.

Editor David Bluemke, MD, PhD, says the journal’s rising impact factor is “representative of the fundamental importance of imaging throughout our hospitals and clinics.”

An imaging OEM is teaming with a multi-omics diagnostics company to offer lung-cancer care teams lab data alongside radiologic findings and clinical histories.

One of the largest private health insurers in the U.S. has gone from considering hybrid PET/CT for cardiac indications “experimental/investigational” to displaying willingness to pay for the modality. 

Rumors have been swirling for more than a year, but a Siemens Healthineers C-suite executive has declared the company’s ultrasound business alive, well and amply resourced.